Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Dermatologicals Market by Dermatological Disease (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, and Alopecia), Drug Type (Prescription-Based Drugs and Over-the-Counter Drugs), and Route of Administration (Topical, Oral, and Parenteral Administration), Global Opportunity Analysis and Industry Forecast, 2018–2026

A03463
Pages: 245
Mar 2020 | 4484 Views
 
Author(s) : Sagar Mukhekar , Onkar Sumant
Tables: 109
Charts: 65
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Dermatologicals Market

Request Now !

The global dermatologicals market accounted for $15,563 million in 2018 and is expected to reach $36,205 million by 2026, registering a CAGR of 10.9% from 2019 to 2026. 

Dermatology is a field of medicine that is engaged in the diagnosis, prevention, and treatment of various diseases related to skin, nails, and hair, such as pigmentation, acne, wrinkles, and psoriasis. Dermatological agents, also known as dermatologicals, are products which are applied topically on the skin. These products are used to treat skin conditions and are also employed to prevent certain skin disorders. Furthermore, dermatologicals are also used for routine skin care to maintain one’s skin. However, some of the dermatologicals are systemic preparations, which are used in patients who are not responsive to topical medications. Moreover, these preparations are used to treat various skin conditions such as acne, dermatitis, and psoriasis.

Dermatologicals Market

Get more information on this report : Request Sample Pages

The major factor that contributes to the growth of dermatologicals market include rise in demand for topical dermatological drugs such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients to treat acne. Furthermore, the rise in awareness about skin diseases, high demand for rapid diagnosis, and surge in incidence of skin cancer and other skin disorders are the factors that boost the growth of the dermatologicals market. However, lack of awareness about the drugs and stringent government regulations restrain the dermatologicals market growth. The development of innovative products and increase in number of mergers & acquisitions by key vendors are expected to provide numerous opportunities for the market growth during the forecast period.

Dermatologicals Market Segmentation  

The dermatologicals market size is studied on the basis of dermatological disease, drug type, route of administration, and region to provide a detailed assessment of the market. On the basis of dermatological disease, it is segmented into acne, dermatitis, psoriasis, skin cancer, rosacea, and alopecia. By drug type, it is bifurcated into prescription-based drugs and over-the-counter drugs. On the basis of route of administration, it is segmented into topical, oral, and parenteral administration. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). 

Segment Review

According to dermatological disease, the psoriasis segment occupied the largest dermatologicals market share in 2018. Furthermore, it is also expected to be the fastest growing segment during the forecast period. The growth of this segment is attributed to surge in the incidence of psoriasis worldwide. Furthermore, rise in awareness related to the use of topical ointments for the management and treatment of psoriasis is another major factor that drives the growth of the dermatologicals market. 

Dermatologicals Market
By Product

Your browser does not support the canvas element.

Psoriasis is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

By drug type, the prescription segment occupied the largest share, owing to surge in skin disorders. Furthermore, skin disorders are severe and require skilled medical attention, which is provided by skin specialists. Moreover, over-the-counter drugs is expected to be the fastest growing segment during the forecast period due to surge in the awareness among general public regarding the availability of dermatologicals. 

Dermatologicals Market
By Type

Your browser does not support the canvas element.

Prescription Based Drugs holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By region, North America accounted for the major dermatologicals market share in 2018 and is expected to continue this trend, owing to easy availability of dermatologicals. Moreover, surge in the incidence of skin disorders such as dermatitis, acne, and psoriasis, is another major reason that contributes to the growth of this dermatologicals market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of dermatologicals. The constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia. As the constant development leads to surge in awareness related to the use of dermatologicals. Furthermore, it also leads to rise in aesthetic consciousness among people which contributes to the growth of the dermatologicals market.

Dermatologicals Market
By Geography

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 12.3% during 2019-2026.

Get more information on this report : Request Sample Pages

The global dermatologicals market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Bayer AG, Johnson & Johnson, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, AstraZeneca, Galderma S.A., Amgen Inc., AbbVie Inc., and Merck KGaA.

Key Benefits for Stakeholders:

  • This report entails a detailed quantitative analysis along with the current global dermatologicals market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The dermatologicals market forecast is studied from 2019 to 2026. 
  • The dermatologicals market size and estimations are based on a comprehensive analysis of key developments in the industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments:

By Dermatological Disease

  • Acne
  • Dermatitis
  • Psoriasis 
  • Skin Cancer 
  • Rosacea 
  • Alopecia 

By Drug Type

  • Prescription-Based Drugs 
  • Over-the-Counter Drugs

By Route of Administration

  • Topical
  • Oral
  • Parenteral Administration

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany 
    • France 
    • UK 
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan 
    • China 
    • India 
    • Australia 
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia 
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top player positioning

3.2.1. Top investment pockets

3.3. Key forces shaping dermatologicals industry/market
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of skin disorders
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in focus on skin care products

3.4.2. Restraint

3.4.2.1. Presence of alternatives for acne treatment

3.4.3. Opportunity

3.4.3.1. High growth potential in developing economies

3.4.4. Impact Analyses

CHAPTER 4: DERMATOLOGICALS MARKET, BY DISEASE

4.1. Overview

4.1.1. Market size and forecast

4.2. Acne

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Dermatitis

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Psoriasis

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Skin Cancer

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Rosacea

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Alopecia

4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

4.8. Others

4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

CHAPTER 5: DERMATOLOGICALS MARKET, BY TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Prescription-Based Drugs

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Over-the-Counter Drugs

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Topical Administration

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Oral Administration

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Parenteral Administration

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: DERMATOLOGICALS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends and opportunities
7.2.2. Market analysis, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. market size and forecast, by disease
7.2.2.1.2. U.S. market size and forecast, by type
7.2.2.1.3. U.S. market size and forecast, by route of administration

7.2.2.2. Canada

7.2.2.2.1. Canada market size and forecast, by disease
7.2.2.2.2. Canada market size and forecast, by type
7.2.2.2.3. Canada market size and forecast, by route of administration

7.2.2.3. Mexico

7.2.2.3.1. Mexico market size and forecast, by disease
7.2.2.3.2. Mexico market size and forecast, by type
7.2.2.3.3. Mexico market size and forecast, by route of administration

7.2.3. North America market size and forecast, by disease
7.2.4. North America market size and forecast, by type
7.2.5. North America market size and forecast, by route of administration

7.3. Europe

7.3.1. Key market trends and opportunities
7.3.2. Market analysis, by country

7.3.2.1. Germany

7.3.2.1.1. Germany market size and forecast, by disease
7.3.2.1.2. Germany market size and forecast, by type
7.3.2.1.3. Germany market size and forecast, by route of administration

7.3.2.2. France

7.3.2.2.1. France market size and forecast, by disease
7.3.2.2.2. France market size and forecast, by type
7.3.2.2.3. France market size and forecast, by route of administration

7.3.2.3. UK

7.3.2.3.1. UK market size and forecast, by dermatological disease
7.3.2.3.2. UK market size and forecast, by type
7.3.2.3.3. UK market size and forecast, by route of administration

7.3.2.4. Italy

7.3.2.4.1. Italy market size and forecast, by dermatological disease
7.3.2.4.2. Italy market size and forecast, by type
7.3.2.4.3. Italy market size and forecast, by route of administration

7.3.2.5. Rest of Europe

7.3.2.5.1. Rest of Europe market size and forecast, by dermatological disease
7.3.2.5.2. Rest of Europe market size and forecast, by type
7.3.2.5.3. Rest of Europe market size and forecast, by route of administration

7.3.3. Europe market size and forecast, by dermatological disease
7.3.4. Europe market size and forecast, by type
7.3.5. Europe market size and forecast, by route of administration

7.4. Asia-Pacific

7.4.1. Key market trends and opportunities
7.4.2. Market analysis, by country

7.4.2.1. Japan

7.4.2.1.1. Japan market size and forecast, by dermatological disease
7.4.2.1.2. Japan market size and forecast, by type
7.4.2.1.3. Japan market size and forecast, by route of administration

7.4.2.2. China

7.4.2.2.1. China market size and forecast, by dermatological disease
7.4.2.2.2. China market size and forecast, by type
7.4.2.2.3. China market size and forecast, by route of administration

7.4.2.3. India

7.4.2.3.1. India market size and forecast, by dermatological disease
7.4.2.3.2. India market size and forecast, by type
7.4.2.3.3. India market size and forecast, by route of administration

7.4.2.4. Rest of Asia-Pacific

7.4.2.4.1. Rest of Asia-Pacific market size and forecast, by dermatological disease
7.4.2.4.2. Rest of Asia-Pacific market size and forecast, by type
7.4.2.4.3. Rest of Asia-Pacific market size and forecast, by route of administration

7.4.3. Asia-Pacific market size and forecast, by dermatological disease
7.4.4. Asia-Pacific market size and forecast, by type
7.4.5. Asia-Pacific market size and forecast, by route of administration

7.5. LAMEA

7.5.1. Key market trends and opportunities
7.5.2. Market analysis, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil market size and forecast, by dermatological disease
7.5.2.1.2. Brazil market size and forecast, by type
7.5.2.1.3. Brazil market size and forecast, by route of administration

7.5.2.2. South Africa

7.5.2.2.1. South Africa market size and forecast, by dermatological disease
7.5.2.2.2. South Africa market size and forecast, by type
7.5.2.2.3. South Africa market size and forecast, by route of administration

7.5.2.3. Saudi Arabia

7.5.2.3.1. Saudi Arabia market size and forecast, by dermatological disease
7.5.2.3.2. Saudi Arabia market size and forecast, by type
7.5.2.3.3. Saudi Arabia market size and forecast, by route of administration

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA market size and forecast, by dermatological disease
7.5.2.4.2. Rest of LAMEA market size and forecast, by type
7.5.2.4.3. Rest of LAMEA market size and forecast, by route of administration

7.5.3. LAMEA market size and forecast, by dermatological disease
7.5.4. LAMEA market size and forecast, by type
7.5.5. LAMEA market size and forecast, by route of administration

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. AstraZeneca plc

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Amgen Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance

8.4. GlaxoSmithKline Plc.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance

8.5. Johnson & Johnson

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance

8.6. Leo Pharma A/S

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. Merck KGaA

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance

8.8. Nestlé S.A

8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Business performance

8.9. Novartis AG

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance

8.10. Pfizer Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL DERMATOLOGICALS MARKET, BY DISEASE, 2018–2026 ($MILLION)
TABLE 02. ACNE DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. DERMATITIS DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. PSORIASIS DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. SKIN CANCER DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. ROSACEA DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. ALOPECIA DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTHERS DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL DERMATOLOGICALS MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 10. PRESCRIPTION-BASED DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. OVER-THE-COUNTER DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12. GLOBAL DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 13. TOPICAL ADMINISTRATION MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 14. ORAL ADMINISTRATION DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 15. PARENTERAL ADMINISTRATION DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16. DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 17. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 18. U.S. DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 19. U.S. DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 20. U.S. DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 21. CANADA DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 22. CANADA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 23. CANADA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 24. MEXICO DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 25. MEXICO DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 26. MEXICO DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 27. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026($MILLION)
TABLE 28. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 29. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2018–2026($MILLION)
TABLE 30. EUROPE DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 31. GERMANY DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 32. GERMANY DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 33. GERMANY DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 34. FRANCE DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 35. FRANCE DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 36. FRANCE DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 37. UK DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 38. UK DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 39. UK DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 40. ITALY DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 41. ITALY DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 42. ITALY DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 43. REST OF EUROPE DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 44. REST OF EUROPE DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 45. REST OF EUROPE DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 46. EUROPE DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026($MILLION)
TABLE 47. EUROPE DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 48. EUROPE DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINSITRATION, 2018–2026($MILLION)
TABLE 49. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 50. JAPAN DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 51. JAPAN DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 52. JAPAN DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 53. CHINA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 54. CHINA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 55. CHINA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 56. INDIA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 57. INDIA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 58. INDIA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 60. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 61. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026($MILLION)
TABLE 63. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 64. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2018–2026($MILLION)
TABLE 65. LAMEA DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 66. BRAZIL DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 67. BRAZIL DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 68. BRAZIL DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 69. SOUTH AFRICA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 70. SOUTH AFRICA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 71. SOUTH AFRICA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 72. SAUDI ARABIA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 73. SAUDI ARABIA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 74. SAUDI ARABIA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 75. REST OF LAMEA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 76. REST OF LAMEA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 77. REST OF LAMEA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 78. LAMEA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026($MILLION)
TABLE 79. LAMEA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 80. LAMEA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 81. ABBVIE: COMPANY SNAPSHOT
TABLE 82. ABBVIE: OPERATING SEGMENTS
TABLE 83. ABBVIE: PRODUCT PORTFOLIO
TABLE 84. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 85. ASTRAZENECA: OPERATING BUSINESS SEGMENT
TABLE 86. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 87. AMGEN: COMPANY SNAPSHOT
TABLE 88. AMGEN: OPERATING SEGMENT
TABLE 89. AMGEN: PRODUCT PORTFOLIO
TABLE 90. GSK: COMPANY SNAPSHOT
TABLE 91. GSK: OPERATING BUSINESS SEGMENTS
TABLE 92. GSK: PRODUCT PORTFOLIO
TABLE 93. J&J: COMPANY SNAPSHOT
TABLE 94. J&J: OPERATING SEGMENTS
TABLE 95. JOHNSON & JOHNSON: PRODUCT PORTFOLIO:
TABLE 96. LEO: COMPANY SNAPSHOT
TABLE 97. LEO: OPERATING BUSINESS SEGMENTS
TABLE 98. LEO: PRODUCT PORTFOLIO
TABLE 99. MERCK: COMPANY SNAPSHOT
TABLE 100. MERCK: OPERATING BUSINESS SEGMENTS
TABLE 101. MERCK: PRODUCT PORTFOLIO
TABLE 102. NESTLÉ: COMPANY SNAPSHOT
TABLE 103. NESTLÉ: PRODUCT PORTFOLIO
TABLE 104. NOVARTIS: COMPANY SNAPSHOT
TABLE 105. NOVARTIS: OPERATING SEGMENTS
TABLE 106. NOVARTIS: PRODUCT PORTFOLIO
TABLE 107. PFIZER: COMPANY SNAPSHOT
TABLE 108. PFIZER: OPERATING SEGMENTS
TABLE 109. PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL DERMATOLOGICALS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, DERMATOLOGICALS MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF ACNE DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DERMATITIS DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PSORIASIS DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF SKIN CANCER DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ROSACEA DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ALOPECIA DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OTHERS DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PRESCRIPTION-BASED DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF OVER-THE-COUNTER DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TOPICAL ADMINISTRATION MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ORAL ADMINISTRATION DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PARENTERAL ADMINISTRATION DERMATOLOGICALS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 22. U.S. DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 23. CANADA DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 24. MEXICO DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 25. GERMANY DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 26. FRANCE DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 27. UK DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 28. ITALY DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 29. REST OF EUROPE DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 30. JAPAN DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 31. CHINA DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 32. INDIA DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 33. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 34. BRAZIL DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 35. SOUTH AFRICA DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 36. SAUDI ARABIA DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 37. REST OF LAMEA DERMATOLOGICALS MARKET, 2018–2026 ($MILLION)
FIGURE 38. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. ABBVIE: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 40. ABBVIE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. ASTRAZENECA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 43. AMGEN: NET SALES, 2017–2018 ($MILLION)
FIGURE 44. AMGEN INC.: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 45. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 46. GSK: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 47. GSK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 48. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 49. J&J: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 50. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 51. LEO: NET SALES, 2016–2018 ($MILLION)
FIGURE 52. LEO: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 53. LEO: REVENUE SHARE BY REGION, 2018(%)
FIGURE 54. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 55. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 56. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 57. NESTLÉ: NET SALES, 2016–2018 ($MILLION)
FIGURE 58. NESTLÉ: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 59. NESTLÉ: REVENUE SHARE BY REGION, 2018(%)
FIGURE 60. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 61. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 62. NOVARTIS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 63. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 64. PFIZER: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 65. PFIZER: REVENUE SHARE BY REGION, 2018 (%)

 
 

Dermatologicals are products which are employed in the treatment of skin disorders such as psoriasis, acne, and dermatitis. These preparations are either used topically or administered orally. Furthermore, they are also administered to a patient via parenteral route. Moreover, dermatological preparations are mostly available as over-the-counter medicines. However, there are dermatological preparations which are prescribed by physicians.

The utilization of dermatologicals has witnessed a significant growth, owing to surge in demand for topical drugs such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients to treat acne. Moreover, surge in awareness about skin diseases and high demand for rapid diagnosis are other factors that boost the growth of the market.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of dermatologicals market is $15,563.00 million in 2018.

A. The forcast period for dermatologicals market is 2019 to 2026

A. The market value of dermatologicals market in 2019 is $17,520.60 million

A. The base year is 2018 in dermatologicals market

A. Top companies such as, as Johnson & Johnson, GlaxoSmithKline Plc., Merck KGaA, Pfizer Inc., and Nestlé S.A. held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Psoriasis segment is the most influencing segment growing in the dermatologicals market owing to increase in the incidences of psoriasis along with skin disorders associated with it, globally.

A. The key trend in the dermatologicals market is the rise in skin disorders across the globe which drives the growth of the market. This leads to surge in the demand for dermatologicals which boots the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 13.2%. This is due to surge in the surge in awareness related to use of dermatologicals for treatment of diseases such as acne, rosacea and others .

A. Dermatologicals are the drugs that are used to treat or prevent conditions related to the skin. Moreover, dermatological preparations are applied directly to the skin by topical application or are administered through the parenteral route

A. Dermatologicals are used to treat skin related disorders such as acne, psoriasis, rosacea and others. For instance, psoriasis require the use of parenteral dermatological preparations for treatment which are mostly available over-the-counter

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Dermatologicals Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts